Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR-Reference-Cited by-同舟云学术

Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR

Published:2001-02-05 Issue:2 Volume:15 Page:181-185
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

Moschetta A.,Stolk M. F. J.,Rehfeld J. F.,Portincasa P.,Slee P. H. TH. J.,Koppeschaar H. P. F.,Van Erpecum K. J.,Vanberge-Henegouwen G. P.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2036.2001.00924.x/fullpdf

Reference23 articles.

1. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly;Plewe;Lancet,1984

2. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995;Lamberts;N Engl J Med,1985

3. Acromegaly;Melmed;N Engl J Med,1990

4. Gallstone during octreotide therapy;Dowling;Metabolism,1992

5. Effects of long term octreotide on gall stone formation and gall bladder function;Bigg-Wither;Br Med J,1992

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultrasonographic evaluation of the gallbladder motor function in the diagnosis and prognosis of intrahepatic cholestasis of pregnancy;BMC Pregnancy and Childbirth;2024-01-02

2. Research progress on the immune microenvironment of the gallbladder in patients with cholesterol gallstones;World Journal of Gastrointestinal Surgery;2022-09-27

3. Octreotide-induced acute life-threatening gallstones after vicarious contrast medium excretion: A case report;World Journal of Clinical Cases;2021-09-06

4. Incident Gallstones During Somatostatin Analog Treatment are Associated with Acute Biliary Complications Especially After Discontinuation;Drugs in R&D;2021-03-29

5. Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment;Pituitary;2020-11-09